Humacyte, Inc. (HUMA) Stock Score, Valuation & Financial Research
Humacyte, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 13/100.
Quick answer for HUMA
Humacyte, Inc. currently has a Wall Street Score of 13/100. The stored market price is $0.57. Its financial score is 4/100. Its valuation score is 0/100. The latest WSS change is +5.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Humacyte, Inc. does
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and f
HUMA financial snapshot
- Wall Street Score:
- 13/100
- Current price:
- $0.57
- Market capitalization:
- $95.8M
- Revenue:
- $2.1M
- Net income:
- $-96.7M
- Free cash flow:
- $-105.9M
- Cash:
- $79.9M
- Total debt:
- $66.2M
- EPS:
- -0.26
- Financial score:
- 4/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-105.9M, showing cash burn in the current stored period.
- The balance sheet shows $79.9M of cash versus $66.2M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +5.1 points: HUMA increased 5.1 points because Asset improved by 11.4 points, Management improved by 40 points.
- The current research record carries a missing revenue history warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 4/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research HUMA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.